Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.47 |
| ▸ | DHFR | P00374 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL830251 | 0.87 | TP53 (0.59) | KDM1AMAPTDHFRTP53SMN1; SMN2 | |
| SCHEMBL830704 | 0.84 | HTT (0.51) | KDM1AMAPTDHFRTP53SMN1; SMN2 | |
| SCHEMBL829774 | 0.84 | MEN1 (0.49) | KDM1AMAPTDHFRTP53SMN1; SMN2 | |
| SCHEMBL830551 | 0.84 | MAPT (0.52) | KDM1AMAPTDHFRTP53SMN1; SMN2 | |
| SCHEMBL828917 | 0.81 | TP53 (0.49) | KDM1AMAPTDHFRTP53SMN1; SMN2 | |
| SCHEMBL829447 | 0.81 | DHFR (0.47) | KDM1AMAPTDHFRTP53KDM4E | |
| SCHEMBL829981 | 0.81 | AURKA (0.48) | KDM1AMAPTDHFRTP53SMN1; SMN2 | |
| SCHEMBL7488303 | 0.74 | KDM1A (0.54) | KDM1AMAPTPDE7ADHFRTP53 | |
| SCHEMBL1845376 | 0.72 | NCF1 (0.60) | MAPTTP53SMN1; SMN2MEN1CYP1A2 | |
| SCHEMBL4394098 | 0.72 | MAPT (0.65) | KDM1AMAPTPDE7ADHFRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143276-B2 | 4-thio substituted quinoline and naphthyridine compounds | XTL BIOPHARMACEUTICALS LTD. (IL) | 2012-03-27 | — | — | US | disclosed |
| US-8143276-B2 | 4-thio substituted quinoline and naphthyridine compounds | XTL BIOPHARMACEUTICALS LTD. (IL) | 2012-03-27 | — | — | US | disclosed |
| US-8143276-B2 | 4-thio substituted quinoline and naphthyridine compounds | XTL BIOPHARMACEUTICALS LTD. (IL) | 2012-03-27 | — | — | US | disclosed |
| EP-2061466-A2 | 4-THIO SUBSTITUTED QUINOLINE AND NAPHTHYRIDINE COMPOUNDS | Xtl Biopharmaceuticals Ltd. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20090054477-A1 | 4-thio substituted quinoline and naphthyridine compounds | PRESIDIO PHARMACEUTICALS, INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090054477-A1 | 4-thio substituted quinoline and naphthyridine compounds | PRESIDIO PHARMACEUTICALS, INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090054477-A1 | 4-thio substituted quinoline and naphthyridine compounds | PRESIDIO PHARMACEUTICALS, INC. | 2009-02-26 | — | — | US | disclosed |
| WO-2008024423-A2 | 4-THIO SUBSTITUTED QUINOLINE AND NAPHTHYRIDINE COMPOUNDS | XTL BIOPHARMACEUTICALS LTD. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024423-A2 | 4-THIO SUBSTITUTED QUINOLINE AND NAPHTHYRIDINE COMPOUNDS | XTL BIOPHARMACEUTICALS LTD. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054477-A1 | 4-thio substituted quinoline and naphthyridine compounds | GTF3C4, HNF4A, TENT4A | KDM1A 2855/4885MAPT 2002/4885PDE7A 2922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.